A newly published study from the Cleveland Clinic’s Lerner Research Institute has added to the growing body of evidence supporting Nuvectis Pharma’s (NASDAQ: NVCT)* NXP900, a novel SRC/YES1 kinase inhibitor.…
Posts published in “Nuvectis Pharma”
Nuvectis Pharma (NASDAQ: NVCT) has reported encouraging interim data from its Phase 1b study of NXP800, a drug candidate designed to treat platinum-resistant, ARID1a-mutated ovarian cancer. This type of cancer…